Detalhe da pesquisa
1.
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
Oncologist
; 26(8): e1418-e1426, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33586299
2.
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Oncologist
; 24(4): 537-548, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842244
3.
Generic oncology drugs: are they all safe?
Lancet Oncol
; 17(11): e493-e501, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27819247
4.
Regulatory and clinical considerations for biosimilar oncology drugs.
Lancet Oncol
; 15(13): e594-e605, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25456378
5.
Payer and provider solutions to utilization management challenges in the management of rare hematologic cancers.
Am J Manag Care
; 29(4 Suppl): S51-S60, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129958
6.
Hepatocellular carcinoma: considerations for managed care professionals.
Am J Manag Care
; 26(10 Suppl): S220-S226, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052639
7.
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
PLoS One
; 15(6): e0234541, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32584835
8.
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).
Cancer Med
; 6(7): 1541-1551, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28635055